Skip to main content
Ananda Pharma Plc logo

Ananda Pharma Plc — Investor Relations & Filings

Ticker · ANAN ISIN · GB00BDQPXQ60 LEI · 894500DFM8VOC5FW4X47 Aquis Stock Exchange Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-12-19 Regulatory Filings
Country GB United Kingdom
Listing Aquis Stock Exchange ANAN

About Ananda Pharma Plc

https://www.anandapharma.co.uk/

Ananda Pharma Plc is a biopharmaceutical company focused on the development of regulatory-approved, cannabinoid-based medicines. The company's primary mission is to create therapies for complex, chronic inflammatory conditions with significant unmet medical needs. Its development pipeline is initially centered on treatments for inflammatory pain conditions, including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and endometriosis, as well as heart failure with preserved ejection fraction (HFpEF). Ananda Pharma's approach covers the full development cycle, from identifying clinical potential and optimizing drug candidates to conducting clinical trials and securing marketing authorizations from regulators.

Recent filings

Filing Released Lang Actions
US Cannabis Rescheduling
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS (Regulatory News Service) platform. It announces a corporate reaction to a US Executive Order regarding the rescheduling of cannabis. Since it is a general corporate announcement regarding business strategy and regulatory environment rather than a specific financial report, dividend notice, or governance filing, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate announcements.
2025-12-19 English
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from Ananda Pharma PLC regarding the results of a General Meeting, specifically detailing the voting outcomes for resolutions including the withdrawal of admission to trading on the AQSE Growth Market. Because the document provides the specific results of shareholder votes, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-12-12 English
Redemption of Unsecured CLNs and Director Dealing
Director's Dealing Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Ananda Pharma PLC. It covers multiple topics: the redemption of convertible loan notes (CAP), the resulting issuance of new shares (SHA), and a formal notification of a director's dealing (DIRS) by the Chairman, Charles Morgan. While it contains elements of multiple categories, the primary regulatory purpose of this specific filing is to disclose the share issuance and the associated director's transaction. Given the structure and the inclusion of the PDMR (Person Discharging Managerial Responsibilities) disclosure table, it is best classified as a Share Issue/Capital Change announcement.
2025-12-03 English
CIPN Ethics Approval
Legal Proceedings Report Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Ananda Pharma PLC regarding the receipt of ethics and MHRA approval for a Phase 2 clinical trial. While it mentions a potential future delisting, the primary purpose of the document is to announce a corporate development (clinical trial progress). Since it does not fit into specific categories like financial reports, M&A, or director dealings, and is a standard regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-12-03 English
Initial Data from Phase 1 Study
Legal Proceedings Report Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Ananda Pharma PLC. The primary content is an update on clinical trial results (Phase 1 study data for MRX1), which falls under general regulatory announcements as it is a corporate update on business operations and clinical progress. While it mentions a future delisting, the core purpose of this specific text is the clinical trial update. Since it does not fit into specific categories like 'Earnings Release' or 'Annual Report', and is a standard regulatory disclosure, 'RNS' is the most appropriate classification.
2025-11-27 English
Posting of Q&A
Delisting Announcement Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Ananda Pharma PLC regarding a Q&A session for shareholders concerning a previously announced delisting proposal. While it discusses a delisting, it is not the formal delisting notice itself, but rather a supplementary communication providing management's answers to shareholder questions. As it serves as a general regulatory announcement and does not fit into the specific categories of delisting or proxy solicitation, it is classified as a general regulatory filing.
2025-11-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.